Skip to main content

Olema Pharmaceuticals, Inc. (OLMA)

NASDAQ: OLMA · Delayed Price · USD
27.39
+0.01 (0.04%)
Pre-market:Sep 20, 2021 5:16 AM EDT
27.38
-1.37 (-4.77%)
At close: Sep 17, 4:00 PM
Market Cap1.08B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out39.56M
EPS (ttm)-2.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume458,279
Open28.90
Previous Close28.75
Day's Range27.25 - 29.00
52-Week Range19.41 - 60.27
Betan/a
Analystsn/a
Price Target56.00 (+104.5%)
Est. Earnings DateNov 9, 2021

About OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Ph...

IndustryBiotechnology
IPO DateNov 19, 2020
Employees36
Stock ExchangeNASDAQ
Ticker SymbolOLMA
Full Company Profile

Financial Performance

Financial Statements

News

Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference

SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

1 week ago - GlobeNewsWire

Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...

2 weeks ago - GlobeNewsWire

Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update

SAN FRANCISCO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...

1 month ago - GlobeNewsWire

Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference

SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development ...

4 months ago - GlobeNewsWire

Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update

SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development ...

4 months ago - GlobeNewsWire

Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

5 months ago - GlobeNewsWire

Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

5 months ago - GlobeNewsWire

Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates

SAN FRANCISCO, March 17, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

6 months ago - GlobeNewsWire

Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Ann...

SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci...

6 months ago - GlobeNewsWire

Olema Oncology to Participate at Upcoming Virtual Investor Conferences

SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...

6 months ago - GlobeNewsWire

Analyst talks Biotech sector, offers three picks for 2021

The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable i...

Other symbols:MORFSDGR
8 months ago - Invezz

Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020

SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...

9 months ago - GlobeNewsWire

Olema Trading $34 Above IPO Price After Only 2 Weeks

Since going public on Nov. 19, shares of Olema Pharmaceuticals Inc.(NASDAQ:OLMA) have soared past the offering price of $19 per share to over $53, giving the San Francisco-based company a market value o...

9 months ago - GuruFocus

Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Add...

SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...

9 months ago - GlobeNewsWire

Olema Oncology Announces Pricing of Initial Public Offering

SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...

10 months ago - GlobeNewsWire